Based on the Novavax Inc stock forecast from 5 analysts, the average analyst target price for Novavax Inc is USD 19.67 over the next 12 months. Novavax Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Novavax Inc is Neutral, which is based on 6 positive signals and 6 negative signals. At the last closing, Novavax Inc’s stock price was USD 8.47. Novavax Inc’s stock price has changed by -1.85% over the past week, -9.12% over the past month and +67.72% over the last year.
No recent analyst target price found for Novavax Inc
No recent average analyst rating found for Novavax Inc
Company Overview Novavax Inc
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. Read Less
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its...Read More
Frequently Asked Questions About Novavax Inc (NVAX) Stock
Based on ratings from 5 analysts Novavax Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 7 buy, 1 sell and 1 hold ratings.
Unfortunately we do not have enough data on NVAX's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for NVAX is USD 19.67 over the next 12 months. The maximum analyst target price is USD 31 while the minimum anlayst target price is USD 9.
NVAX stock's Price/Earning ratio is 12.89.
Our analysis grades NVAX stock's Price / Earning ratio at F. This means that NVAX stock's Price/Earning ratio is above 62% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this NVAX may be a overvalued for its sector.
The last closing price of NVAX's stock was USD 8.47.
The most recent market capitalization for NVAX is USD 1.46B.
Based on targets from 5 analysts, the average taret price for NVAX is projected at USD 19.67 over the next 12 months.
This means that NVAX's stock price may go up by +132.19% over the next 12 months.
We can't find any ETFs which contains Novavax Inc's stock.
As per our most recent records Novavax Inc has 1,543 Employees.
Novavax Inc's registered address is 700 Quince Orchard Road, Gaithersburg, MD, United States, 20878.
You can get more information about it from Novavax Inc's website at https://www.novavax.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Novavax Inc (NVAX) Stock
Based on ratings from 5 analysts Novavax Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 7 buy, 1 sell and 1 hold ratings.
Unfortunately we do not have enough data on NVAX's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for NVAX is USD 19.67 over the next 12 months. The maximum analyst target price is USD 31 while the minimum anlayst target price is USD 9.
NVAX stock's Price/Earning ratio is 12.89.
Our analysis grades NVAX stock's Price / Earning ratio at F. This means that NVAX stock's Price/Earning ratio is above 62% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this NVAX may be a overvalued for its sector.
The last closing price of NVAX's stock was USD 8.47.
The most recent market capitalization for NVAX is USD 1.46B.
Based on targets from 5 analysts, the average taret price for NVAX is projected at USD 19.67 over the next 12 months.
This means that NVAX's stock price may go up by +132.19% over the next 12 months.
We can't find any ETFs which contains Novavax Inc's stock.
As per our most recent records Novavax Inc has 1,543 Employees.
Novavax Inc's registered address is 700 Quince Orchard Road, Gaithersburg, MD, United States, 20878.
You can get more information about it from Novavax Inc's website at https://www.novavax.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NVAX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
